ART001
ATTR (Transthyretin Amyloidosis)
Phase 1Active (IIT study initiated Aug 2023, FDA RMAT designation May 2025)
Key Facts
Indication
ATTR (Transthyretin Amyloidosis)
Phase
Phase 1
Status
Active (IIT study initiated Aug 2023, FDA RMAT designation May 2025)
Company
About AccurEdit Therapeutics
A clinical-stage biotech pioneering in vivo CRISPR gene editing therapies with a lead program for ATTR and an integrated platform.
View full company profile